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www.sciencedirect.comEDITORIALChanging paradigms in the treatment of diabetic
retinopathyThe world is facing an epidemic of diabetes mellitus.
Currently, more than 200 million people in the world have dia-
betes and it is predicted that this number will double in about
20 years. Diabetic retinopathy is the most common microvas-
cular complication of diabetes and remains one of the leading
causes of blindness worldwide among adults aged 20–74 years.
The prevalence of diabetic retinopathy increases with the dura-
tion of diabetes, and nearly all persons with type 1 diabetes
and more than 60% of those with type 2 have some retinopa-
thy after 20 years. The two most important visual complica-
tions of diabetic retinopathy are diabetic macular edema and
proliferative diabetic retinopathy.
Five large randomized controlled trials provided the scien-
tiﬁc basis for care in the diabetic patient to preserve vision.
The Diabetes Control and Complications Trial, the United
Kingdom Prospective Diabetes Study, the Diabetic Retinopa-
thy Study, the Early Treatment Diabetic Retinopathy Study
and the Diabetic Retinopathy Vitrectomy Study demon-
strated that strict metabolic control early in the course of
diabetes, tight blood pressure control, panretinal photocoag-
ulation, focal/grid laser photocoagulation, and early vitrec-
tomy in patients with type 1 diabetes who had recent
vitreous hemorrhage were effective at slowing the progression
of retinopathy and reducing visual loss. However, due to the
limitations of the current treatments, new therapeutic ap-
proaches are being developed. Intravitreal triamcinolone ace-
tonide is reported to generate favorable results in the
treatment of diffuse diabetic macular edema. However, the
Diabetic Retinopathy Clinical Research Network demon-
strated that focal/grid photocoagulation is a better treatment
than intravitreal triamcinolone acetonide in eyes with diabetic
macular edema. In addition, triamcinolone is associated with
risks of elevated intraocular pressure and cataract. Anti-vas-1319-4534 ª 2011 King Saud University. Production and hosting by
Elsevier B.V. All rights reserved.
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treatment to laser photocoagulation or vitrectomy. Vitrec-
tomy with the removal of the posterior hyaloid without inter-
nal limiting membrane peeling seems to be effective in eyes
with persistent diabetic macular edema, particularly in those
associated with vitreomacular traction (Abu El-Asrar and
Al-Mezaine, 2010a). Our understanding of the role of the vit-
reous body in diabetic retinopathy has led investigators to
use pharmacologic vitreolysis in the management of diabetic
retinopathy. The agents used are puriﬁed ovine hyaluronidase
(vitrase), autologous plasmin and plasmin. Pilot studies dem-
onstrated that ovine hyaluronidase helps to clear vitreous
hemorrhage. Autologous plasmin was a safe and effective ad-
junct to vitrectomy for diabetic macular edema and prolifer-
ative diabetic retinopathy. Intravitreal injection of autologous
plasmin enzyme before surgery was useful in inducing phar-
macologic posterior vitreous detachment that allowed a more
complete and less traumatic posterior vitreous cortex removal
with a smooth retinal surface. In addition, the proliferative
membranes became softened and were easily peeled without
retinal tears. Intravitreal injection of autologous plasmic en-
zyme without the performance of vitrectomy was found to in-
duce posterior vitreous detachment and reduced macular
thickening due to refractory diffuse diabetic macular edema
(Abu El-Asrar and Al-Mezaine, 2010b). Other emerging ther-
apies include long-term-lipid-lowering therapy with fenoﬁ-
brate, renin–angiotensin system blockers, peroxisome
proliferator-activated receptor gamma agonists, protein ki-
nase C b inhibitors, islet cell transplantation, and micropulse
subthreshold diode laser (Abu El-Asrar et al., 2009). A Better
understanding of the underlying molecular and biochemical
mechanisms involved in diabetic retinopathy will lead to the
development of targeted therapeutic interventions. The
microvasculature of the retina responds to hyperglycemia
through a number of biochemical changes, including activa-
tion of protein kinase C, increased advanced glycation end
products formation, polyol pathway and oxidative stress,
and activation of the renin–angiotensin system. There is an
accumulating body of evidence that inﬂammation and neuro-
degeneration play a prominent role in the pathogenesis of
diabetic retinopathy (Abu El-Asrar et al., 2009). In this issue,
the recent advances in the treatment of diabetic retinopathy
are discussed.
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